Keyphrases:

ibandronic_acid
BIG_TOKEN__¡¬634_patent__BIG_TOKEN
osteoporosis
bone
ibandronate
BIG_TOKEN__¡¬957_patent__BIG_TOKEN
single_day
once
acceptable_salt
orally
====================================
top sentences:

A method for treating or inhibiting postmenopausal_osteoporosis in a postmenopausal_woman in need of treatment or inhibition of postmenopausal_osteoporosis by administration of a pharmaceutically acceptable_salt of ibandronic_acid , comprising : ( a ) commencing the administration of the pharmaceutically acceptable_salt of ibandronic_acid by orally administering to the postmenopausal_woman , on a single_day , a first dose in the form of a tablet , wherein the tablet comprises an amount of the pharmaceutically acceptable_salt of ibandronic_acid that is equivalent to about 150 mg of ibandronic_acid ; and ( b ) continuing the administration by orally administering , once monthly on a single_day , a tablet comprising an amount of the pharmaceutically acceptable_salt of ibandronic_acid that is equivalent to about 150 mg of ibandronic_acid .
6.093365
Bisphosphonates are `` potent inhibitors of bone resorption . ''
5.707052
Claims 1-8 of the BIG_TOKEN__¡¬634_patent__BIG_TOKEN and claims 1-10 of the ¡¬ 957 patent are at issue in this case and describe a method of treating osteoporosis consisting of orally administering about 150 mg of ibandronic_acid once monthly on a single_day .
5.509594
Osteoporosis is a disease characterized by abnormal bone resorption .
5.456095
Roche owns the BIG_TOKEN__¡¬634_patent__BIG_TOKEN and the BIG_TOKEN__¡¬957_patent__BIG_TOKEN , which is the parent of the BIG_TOKEN__¡¬634_patent__BIG_TOKEN .
5.338673
